Mark D. Tyson, MD

Mark D. Tyson, MD

Mark D. Tyson, MD | Urologic Oncologist, Mayo Clinic

Articles by Mark D. Tyson, MD

Cretostimogene for Bladder Cancer: BOND-003 Study Ramifications

Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | February 11, 2025

Dr. Tyson shares insights on the potential role of cretostimogene in treating BCG-unresponsive NMIBC, based on BOND-003 data.

BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer

Mark D. Tyson, MDNon-Muscle Invasive Urothelial Carcinoma | February 11, 2025

Dr. Tyson reviews the findings from Cohort P of the BOND-003 trial on cretostimogene grenadenorepvec for NMIBC.